TAAR1 and schizophrenia: Another company, Sunovion Pharmaceuticals (now Sumitomo Pharma), developed a TAAR1/5-HT1AR agonist, SEP-363856 (Ulotaront) [22], which evidenced promising results in a phase II clinical trial for schizophrenia [23,24,25,26].